Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2020Drug Design Development and TherapyOpen Access

Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients

View Full Paper
Ask AI
Bookmark
Share

Authors

LLLu LiXWXiaojuan WangRWRongrong Wang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Li et al. (2020) studied this question.

synapsesocial.com/papers/6a20b2fef778797513eb8942https://doi.org/10.2147/dddt.s259058
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pharmacokinetics, Metabolism, and Excretion of the Antiviral Drug Arbidol in Humans2013 · 74 citations
  2. 2First Case of 2019 Novel Coronavirus in the United States2020 · 6,408 citations
  3. 3Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol2020 · 64 citations
  4. 4Remdesivir for the Treatment of Covid-19 — Final Report2020 · 7,756 citations